What does SCIENTIFIC & MEDICAL TECHNOLOGIES do?

SCIENTIFIC & MEDICAL TECHNOLOGIES is a printing company in Machelen (Brab.). Private Limited, started on 10 April 2000, 1 establishment.

What is the address of SCIENTIFIC & MEDICAL TECHNOLOGIES?

The registered office of SCIENTIFIC & MEDICAL TECHNOLOGIES is located at Jan Veldmansstraat 77, 1830 Machelen (Brab.).

Is SCIENTIFIC & MEDICAL TECHNOLOGIES still active?

Yes. According to the CBE (16 September 2026) SCIENTIFIC & MEDICAL TECHNOLOGIES is active, legal situation “Normale toestand”, started on 10 April 2000.

Is SCIENTIFIC & MEDICAL TECHNOLOGIES registered on Peppol?

Yes, SCIENTIFIC & MEDICAL TECHNOLOGIES is registered on the Peppol network with ID 0208:0471654283.

What is the enterprise number of SCIENTIFIC & MEDICAL TECHNOLOGIES?

The enterprise number of SCIENTIFIC & MEDICAL TECHNOLOGIES is BE0471654283.

When was SCIENTIFIC & MEDICAL TECHNOLOGIES founded?

SCIENTIFIC & MEDICAL TECHNOLOGIES was founded on 10 April 2000.

Who are the directors of SCIENTIFIC & MEDICAL TECHNOLOGIES?

According to the 2025 annual accounts, the directors of SCIENTIFIC & MEDICAL TECHNOLOGIES are: Marc SWALLYEE.

Is SCIENTIFIC & MEDICAL TECHNOLOGIES a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 10 April 2000; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did SCIENTIFIC & MEDICAL TECHNOLOGIES make in 2025?

SCIENTIFIC & MEDICAL TECHNOLOGIES recorded a loss after taxes of € 37,436 in financial year 2025.

What is the revenue of SCIENTIFIC & MEDICAL TECHNOLOGIES?

As a small company, SCIENTIFIC & MEDICAL TECHNOLOGIES is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -18,458.

SCIENTIFIC & MEDICAL TECHNOLOGIES (Private Limited)

Dossier SCIENTIFIC & MEDICAL TECHNOLOGIES, printed on 16 September 2026 from databakkes.be/en/0471654283/scientific-medical-technologies. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

SCIENTIFIC & MEDICAL TECHNOLOGIES from Machelen (Brab.), company number BE0471654283, closed financial year 2025 with a result of € -37,436 after tax. For that financial year SCIENTIFIC & MEDICAL TECHNOLOGIES recorded a gross margin of € -18,458 and equity of € 15,210. Compared with financial year 2024, the result moved from € 23,756 to € -37,436. The company made a loss. The buffer shrank hard: equity is 71 % below last year. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.

What it is worth Shrank hard

€ 15,210

▼ 71% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -37,436

▼ still € 23,756 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 66,225

▼ 36% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -3,382.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 7,048

▼ 46% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Taxes

€ 9,078

▼ 9% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 29,326 Gross margin 2022: € 29,326 First fiscal year in the series	€ -2,857 Gross margin 2023: € -2,857 ▼ € 32,183 vs 2022 (€ 29,326) Unfavourable step	€ 58,900 Gross margin 2024: € 58,900 ▲ € 61,757 vs 2023 (€ -2,857) Favourable step	€ -18,458 Gross margin 2025: € -18,458 ▼ € 77,358 vs 2024 (€ 58,900) Unfavourable step	▼ € 77,358
Profit after taxes	€ -1,509 Profit after taxes 2022: € -1,509 First fiscal year in the series	€ -31,972 Profit after taxes 2023: € -31,972 ▼ € 30,463 vs 2022 (€ -1,509) Unfavourable step	€ 23,756 Profit after taxes 2024: € 23,756 ▲ € 55,728 vs 2023 (€ -31,972) Favourable step	€ -37,436 Profit after taxes 2025: € -37,436 ▼ € 61,192 vs 2024 (€ 23,756) Unfavourable step	▼ € 61,192
Equity	€ 121,748 Equity 2022: € 121,748 First fiscal year in the series	€ 89,776 Equity 2023: € 89,776 ▼ 26% vs 2022 (€ 121,748) Unfavourable step	€ 52,646 Equity 2024: € 52,646 ▼ 41% vs 2023 (€ 89,776) Unfavourable step	€ 15,210 Equity 2025: € 15,210 ▼ 71% vs 2024 (€ 52,646) Unfavourable step	▼ 71%
Total debts	€ 54,629 Total debts 2022: € 54,629 First fiscal year in the series	€ 44,635 Total debts 2023: € 44,635 ▼ 18% vs 2022 (€ 54,629) Favourable step	€ 85,906 Total debts 2024: € 85,906 ▲ 92% vs 2023 (€ 44,635) Unfavourable step	€ 66,823 Total debts 2025: € 66,823 ▼ 22% vs 2024 (€ 85,906) Favourable step	▼ 22%
Cash	€ 102,654 Cash 2022: € 102,654 First fiscal year in the series	€ 70,908 Cash 2023: € 70,908 ▼ 31% vs 2022 (€ 102,654) Unfavourable step	€ 102,925 Cash 2024: € 102,925 ▲ 45% vs 2023 (€ 70,908) Favourable step	€ 66,225 Cash 2025: € 66,225 ▼ 36% vs 2024 (€ 102,925) Unfavourable step	▼ 36%
Retained profit	€ 103,156 Retained profit 2022: € 103,156 First fiscal year in the series	€ 71,184 Retained profit 2023: € 71,184 ▼ 31% vs 2022 (€ 103,156) Unfavourable step	€ 34,054 Retained profit 2024: € 34,054 ▼ 52% vs 2023 (€ 71,184) Unfavourable step	€ -3,382 Retained profit 2025: € -3,382 ▼ € 37,436 vs 2024 (€ 34,054) Unfavourable step	▼ € 37,436
Dividend	€ 22,056 Dividend 2022: € 22,056 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 22,056) Unchanged	€ 60,886 Dividend 2024: € 60,886 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 60,886) Unchanged	▼ 100%
Bank debt	€ 35,785 Bank debt 2022: € 35,785 First fiscal year in the series	€ 21,137 Bank debt 2023: € 21,137 ▼ 41% vs 2022 (€ 35,785) Favourable step	€ 6,264 Bank debt 2024: € 6,264 ▼ 70% vs 2023 (€ 21,137) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 6,264) Favourable step	▼ 100%
Balance sheet total	€ 176,376 Balance sheet total 2022: € 176,376 First fiscal year in the series	€ 134,411 Balance sheet total 2023: € 134,411 ▼ 24% vs 2022 (€ 176,376) Unchanged	€ 138,552 Balance sheet total 2024: € 138,552 ▲ 3% vs 2023 (€ 134,411) Unchanged	€ 82,033 Balance sheet total 2025: € 82,033 ▼ 41% vs 2024 (€ 138,552) Unchanged	▼ 41%

Key figures of SCIENTIFIC & MEDICAL TECHNOLOGIES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to SCIENTIFIC & MEDICAL TECHNOLOGIES?

What happened at SCIENTIFIC & MEDICAL TECHNOLOGIES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 14, 2026 New annual accounts for financial year 2025: loss of € 37,436 (▼ € 61,192 vs 2024). Source: NBB ↗
May 15, 2000 New establishment in Machelen (Brab.). KBO
Apr 10, 2000 Start of the company according to the CBE. KBO

In short

From € 1,509 loss in 2022 to € 37,436 loss in 2025.

Paid € 14,764 in corporate taxes since 2022.

Best year ever: 2024, with € 23,756 profit.

Paid out € 82,942 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at SCIENTIFIC & MEDICAL TECHNOLOGIES? We notify you, reason included.

Follow SCIENTIFIC & MEDICAL TECHNOLOGIES

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Marc SWALLYEE

SCIENTIFIC & MEDICAL TECHNOLOGIES

Behind SCIENTIFIC & MEDICAL TECHNOLOGIES is Marc SWALLYEE.

See the full network in the app

Directors

According to the 2025 annual accounts

Marc SWALLYEE

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Jan Veldmansstraat 77

1830 Machelen (Brab.)

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0471.654.283

VAT number

BE 0471.654.283

Registered office

Jan Veldmansstraat 77, 1830 Machelen (Brab.)

Names & denominations

SCIENTIFIC & MEDICAL TECHNOLOGIES · SCIMEDTECH

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

10 April 2000

Peppol

Active · Active since 16 Oct 2025

Activities · NACE

Prepress- en premediadiensten

Hulpactiviteiten in verband met drukkerijen

Activiteiten van reclamebureaus

Publiciteitsagentschappen

View on CBE Public ↗ Annual accounts (NBB) ↗